Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment

American Journal of Clinical Pathology

Volumn 128, Issue 1, 2007, Pages 143-149

  Paniccia, Rita ^a,b   Antonucci, Emilia ^a   Gori, Anna Maria ^a   Marcucci, Rossella ^a   Poli, Serena ^a   Romano, Eloisa ^a   Valente, Serafina ^b   Giglioli, Cristina ^b   Fedi, Sandra ^a   Gensini, Gian Franco ^a,b,c   Abbate, Rosanna ^a   Prisco, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Aggregation; Aspirin; Platelet; Point of care testing

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; HEPARIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD; COMPARATIVE STUDY; HEART MUSCLE ISCHEMIA; HOSPITAL INFORMATION SYSTEM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; TICLOPIDINE;

EID: 34547104001     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/0G1PEJ00J8KP8357     Document Type: Article

References (33)

1. Antiplatelet Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
3. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-1397.
4. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005;45:1748-1752.
5. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol. 2005;45:1753-1756.
6. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216-235.
7. Michelson AD, Cattaneo M, Eikelboom JW, et al, and the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis and Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309-1311.
8. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J. 1998;135(5 pt 2 suppl):S170-S178.
9. Harrison P. Progress in the assessment of platelet function. Br J Haematol. 2000;111:733-744.
10. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202.
11. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis. 2004;15:295-301.
12. Coleman J, Wang J, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care. 2004;3:77-82.
13. Coakley M, Self R, Marchant W, et al. Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia. 2005;60:1173-1178.
14. Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost. 2006;4:813-819.
15. Jilma B, Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100) [letter]. Am J Cardiol. 2001;88:1348-1349.
16. Andersen K, Hurlen M, Arnesen H, et al. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002;108:37-42.
17. Wheeler GL, Braden GA, Steinhubl SR, et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 2002;143:602-611.
18. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005;36:1001-1005.
19. Williams MS, Kickler TS, Vaidya D, et al. Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis. 2006;21:241-247.
20. Hayward CP, Harrison P, Cattaneo M, et al, and the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312-319.
21. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006;27:647-654.
22. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005;51:957-965.
23. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost. 2000;83:316-321.
24. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620-625.
25. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
26. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331-2336.
27. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol. 2005;101:71-76.
28. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol. 2002;9:407-415.
29. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol. 2004;124:80-85.
30. Homoncik M, Blann AD, Hollenstein U, et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol. 2000;111:1250-1252.
31. Mannini L, Marcucci R, Paniccia R, et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin Hemorheol Microcirc. 2006;35:175-181.
32. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
33. Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100 [letter]. J Thromb Haemost. 2004;2:2278-2279.